Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Candesartan Cilexetil

FDA-approved product (tablet, oral), marketed as Atacand, Candesartan Cilexetil.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Candesartan Cilexetil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Congestive heart failure
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Candesartan Cilexetil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Candesartan Cilexetil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

    NCT02254447 · start 2014-12-02

    Registered record
    Registry ID
    NCT02254447
    Conditions
    Cardiovascular Disease
    Interventions
    Candesartan Cilexetil in formulation 1; Candesartan Cilexetil in formulation 2; ATACAND
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-12-02
    Completion
    2015-01-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionCandesartan Cilexetil in formulation 1; Candesartan Cilexetil in formulation 2; ATACAND
    PhasePhase 1
    Registry statusCompleted

  • Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

    NCT02944734 · start 2014-09

    Registered record
    Registry ID
    NCT02944734
    Conditions
    Essential Hypertension
    Interventions
    Candesartan Cilexetil 8mg; Candesartan Cilexetil 16mg; Amlodipine 5mg; Amlodipine 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-09
    Completion
    2015-12
    Enrolment
    392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionCandesartan Cilexetil 8mg; Candesartan Cilexetil 16mg; Amlodipine 5mg; Amlodipine 10mg
    PhasePhase 2
    Registry statusCompleted

  • CAndesartan vs LIsinopril Effects on the BRain

    NCT01984164 · start 2014-08-20

    Registered record
    Registry ID
    NCT01984164
    Conditions
    Hypertension; Mild Cognitive Impairment
    Interventions
    Candesartan; Lisinopril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-08-20
    Completion
    2018-12-03
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Mild Cognitive Impairment
    InterventionCandesartan; Lisinopril
    PhasePhase 2
    Registry statusCompleted

  • Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)

    NCT02186496 · start 2014-07

    Registered record
    Registry ID
    NCT02186496
    Conditions
    Hypertension
    Interventions
    CKD-330 8/5mg; Candesartan 8mg and Amlodipine 5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-07
    Completion
    2014-11
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionCKD-330 8/5mg; Candesartan 8mg and Amlodipine 5mg
    PhasePhase 1
    Registry statusCompleted

  • Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients

    NCT02200822 · start 2014-07

    Registered record
    Registry ID
    NCT02200822
    Conditions
    Heart Failure (HF)
    Interventions
    beta blockers; RAAS blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2019-02
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure (HF)
    Interventionbeta blockers; RAAS blockers
    PhasePhase 4
    Registry statusCompleted

  • Bioequivalence Study of CJ-30059

    NCT02173912 · start 2014-06

    Registered record
    Registry ID
    NCT02173912
    Conditions
    Healthy Volunteers
    Interventions
    Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference); CJ-30059 (Test)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2014-06
    Completion
    2014-08
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionCandesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference); CJ-30059 (Test)
    PhasePhase 1
    Registry statusUnknown

  • A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323

    NCT02094924 · start 2014-04-17

    Registered record
    Registry ID
    NCT02094924
    Conditions
    Hypertension
    Interventions
    GSK587323; FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04-17
    Completion
    2014-05-23
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionGSK587323; FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin

    NCT02079506 · start 2014-02

    Registered record
    Registry ID
    NCT02079506
    Conditions
    Healthy
    Interventions
    Candesartan; Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02
    Completion
    2014-02
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCandesartan; Rosuvastatin
    PhasePhase 1
    Registry statusCompleted

  • Angiotensin II Antagonist in Severe Sepsis

    NCT01992796 · start 2014-01

    Registered record
    Registry ID
    NCT01992796
    Conditions
    Severe Sepsis
    Interventions
    Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2017-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Sepsis
    InterventionIrbesartan
    PhasePhase 3
    Registry statusUnknown

  • Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

    NCT01976572 · start 2013-10

    Registered record
    Registry ID
    NCT01976572
    Conditions
    Hyperphosphatemia; Chronic Kidney Disease
    Interventions
    colestilan; candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperphosphatemia; Chronic Kidney Disease
    Interventioncolestilan; candesartan
    PhasePhase 1
    Registry statusCompleted

  • Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation

    NCT01162902 · start 2013-09

    Registered record
    Registry ID
    NCT01162902
    Conditions
    Stable Angina
    Interventions
    Diltiazem treated group; Bisoprolol treated group; Candesartan treated group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-09
    Completion
    2015-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStable Angina
    InterventionDiltiazem treated group; Bisoprolol treated group; Candesartan treated group
    PhasePhase 4
    Registry statusUnknown

  • Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression

    NCT01794455 · start 2013-05

    Registered record
    Registry ID
    NCT01794455
    Conditions
    Depression; Hypertension
    Interventions
    Sertraline; Candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-05
    Completion
    2015-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Hypertension
    InterventionSertraline; Candesartan
    PhasePhase 4
    Registry statusTerminated

  • Recurrent Stroke Prevention Clinical Outcome Study

    NCT01198496 · start 2010-10

    Registered record
    Registry ID
    NCT01198496
    Conditions
    Hypertension; Stroke; Blood Pressure
    Interventions
    Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2010-10
    Completion
    2019-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Stroke; Blood Pressure
    InterventionLosartan, Losartan and HCTZ, Amlodipine , Spironolactone
    PhasePhase 4
    Registry statusUnknown

  • Cognitive Function and Electrocardiogram (ECG) During Hypoglycemia and Blockade of the Renin-angiotensin System

    NCT01116180 · start 2010-04

    Registered record
    Registry ID
    NCT01116180
    Conditions
    Type 1 Diabetes; Hypoglycemia
    Interventions
    Angiotensin II receptor antagonists (Candesartan); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-04
    Completion
    2013-02
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes; Hypoglycemia
    InterventionAngiotensin II receptor antagonists (Candesartan); Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

    NCT01025843 · start 2009-12-01

    Registered record
    Registry ID
    NCT01025843
    Conditions
    Hypertension
    Interventions
    MK-5478; Comparator: Candesartan cilexetil; Comparator: Pbo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-12-01
    Completion
    2010-05-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionMK-5478; Comparator: Candesartan cilexetil; Comparator: Pbo
    PhasePhase 1
    Registry statusCompleted